LUGANO-MADRID –Nearly 23,000 participants from 131 countries are set to attend the ESMO 2017 Congress, which is being held 8 to 12 September in Madrid.
Groundbreaking and practice-changing research will be presented on lung cancer, melanoma, ovarian cancer, breast cancer, and head and neck cancer.
A total of 3,260 abstracts were submitted to this year’s event, of which 1,736 were selected for presentation at ESMO 2017. Highly anticipated results will be revealed in the 55 late breaking abstracts.
There will be numerous simultaneous publications of ESMO 2017 research in leading scientific journals including The New England Journal of Medicine, The Lancet, and Annals of Oncology.
The packed press programme features 31 press releases, seven press conferences, and 41 speakers. Topics include the needs of adolescent and young adult cancer patients, expanding the use of approved drugs, the updated version of the ESMO Magnitude of Clinical Benefit Scale to grade orphan drugs, patients’ changing perception of chemotherapy side effects and much more.
More than 300 journalists are accredited to attend the five day programme which will hold three presidential symposia. Share the news at #ESMO17
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO 2017 Congress
The ESMO Press Programme (press releases, press conference schedule, studies included in the press programme) can be found here
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 16,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.